基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响

doi:10.11904/j.issn.1002-3070.2022.01.017

摘要/Abstract

摘要： 乳腺癌作为全球发病率最高的癌症,严重威胁女性的生命健康。Luminal A型乳腺癌是最常见的乳腺癌亚型,具有细胞分化程度高、侵袭力低的特点。研究发现,Luminal A型乳腺癌的腋窝淋巴结转移率仍可达到26.3%,且淋巴结转移数量越多,其5年生存率越低,所以有相当数量的Luminal A型乳腺癌患者会有较差的预后。本文主要从患者的基因表达与多基因检测以及生物标志物等方面综述影响Luminal A型乳腺癌预后的相关因素,从而为临床决策和预测患者预后提供参考资料。

关键词: Luminal A型, 乳腺癌, 预后

Abstract: Breast cancer,as the world's highest incidence of cancer,seriously threatens the life and health of women.Luminal A-like breast cancer is the most common subtype of breast cancer,with the characteristics of high degree of cell differentiation and low invasiveness.The study found that the axillary lymph node metastasis rate of Luminal A breast cancer can still reach 26.3%,and the greater the number of lymph node metastases,the lower the 5-year survival rate,so there are still a considerable number of Luminal A breast cancer patients who will have a poor the prognosis.This article mainly reviews the factors affecting the prognosis of Luminal A breast cancer from the aspects of gene expression,polygene detection and biomarkers,so as to provide reference for clinical decision-making and predicting the prognosis of patients.

Key words: Luminal type A, Breast cancer, Prognosis

中图分类号:

R737.9

曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.

CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer[J]. Journal of Practical Oncology, 2022, 36(1): 89-93.

参考文献

1 Ferlay J,Colombet M,Soerjomataram I,et al.Cancer statistics for the year 2020:an overview[J].Int J Cancer,2021.
2 Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
3 Hennigs A,Riedel F,Gondos A,et al.Prognosis of breast cancer molecular subtypes in routine clinical care:a large prospective cohort study[J].BMC Cancer,2016,16(1):734.
4 Atahan IL,Yildiz F,Ozyigit G,et al.Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer[J].Acta Oncol,2008,47(2):232-238.
5 Kim HS,Park I,Cho HJ,et al.Analysis of the potent prognostic factors in luminal-type breast cancer[J].J Breast Cancer,2012,15(4):401-406.
6 Xue C,Wang X,Peng R,et al.Distribution,clinicopathologic features and survival of breast cancer subtypes in Southern China[J].Cancer Science,2012,103(9):1679-1687.
7 Kasangian AA,Gherardi G,Biagioli E,et al.The prognostic role of tumor size in early breast cancer in the era of molecular biology[J].PLoS One,2017,12(12):e0189127.
8 Wang F,He W,Qiu H,et al.Lymph node ratio and pN staging show different superiority as prognostic predictors depending on the number of lymph nodes dissected in Chinese patients with luminal A breast cancer[J].Clin Breast Cancer,2012,12(6):404-411.
9 Vinh-Hung V,Joseph SA,Coutty N,et al.Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer[J].Oncologist,2010,15(10):1050-1062.
10 Liu P,Wang Y,Li X.Targeting the untargetable KRAS in cancer therapy[J].Acta Pharm Sin B,2019,9(5):871-879.
11 Hwang KT,Kim BH,Oh S,et al.Prognostic Role of KRAS mRNA Expression in Breast Cancer[J].J Breast Cancer,2019,22(4):548-561.
12 Li Y,Zhang X,Qiu J,et al.Comparisons of p53,KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis[J].J buon,2019,24(6):2361-2368.
13 Schon K,Tischkowitz M.Clinical implications of germline mutations in breast cancer:TP53[J].Breast Cancer Res Treat,2018;167(2):417-423.
14 Williams LA,Butler EN,Sun X,et al.TP53 protein levels,RNA-based pathway assessment,and race among invasive breast cancer cases[J].NPJ Breast Cancer,2018,4(13).
15 Kocak A,Heselmeyer-Haddad K,Lischka A,et al.High levels of chromosomal copy number alterations and TP53 mutations correlate with poor outcome in younger breast cancer patients[J].Am J Pathol,2020,190(8):1643-1656.
16 Fountzilas G,Giannoulatou E,Alexopoulou Z,et al.TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting[J].Oncotarget,2016,7(22):32731-32753.
17 Silwal-Pandit L,Vollan HK,Chin SF,et al.TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance[J].Clin Cancer Res,2014,20(13):3569-3580.
18 Aure MR,Vitelli V,Jernström S,et al.Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome[J].Breast cancer research,BCR,2017,19(1):44.
19 Esquela-Kerscher A,Slack FJ.Oncomirs-microRNAs with a role in cancer[J].Nature reviews Cancer,2006,6(4):259-69.
20 McAnena P,Tanriverdi K,Curran C,et al.Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer[J].BMC cancer,2019,19(1):436.
21 McDermott AM,Miller N,Wall D,et al.Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer[J].PLoS One,2014,9(1):e87032.
22 Kornienko AE,Guenzl PM,Barlow DP,et al.Gene regulation by the act of long non-coding RNA transcription[J].BMC Biol,2013,11:59.
23 Marini A,Lena AM,Panatta E,et al.Ultraconserved long non-coding RNA uc.63 in breast cancer[J].Oncotarget,2017,8(22):35669-35680.
24 Syed YY.Oncotype DX breast recurrence score(®):a review of its use in early-stage breast cancer[J].Mol Diagn Ther,2020,24(5):621-632.
25 Ahmed S,Pati S,Le D,et al.The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer[J].J Surg Oncol,2020,122(2):144-154.
26 Audeh W,Blumencranz L,Kling H,et al.Prospective validation of a genomic assay in breast cancer:the 70-gene mammaprint assay and the MINDACT Trial[J].Acta medica academica,2019,48(1):18-34.
27 Li SC,Stucky A,Chen X,et al.Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel[J].Oncotarget,2018,9(70):33290-33301.
28 Fatima A,Tariq F,Malik MFA,et al.Copy number profiling of mammaprint^TM genes reveals association with the prognosis of breast cancer patients[J].Journal of breast cancer,2017,20(3):246-253.
29 Shi YJ,Tsang JY,Ni YB,et al.FGFR1 is an adverse outcome indicator for luminal A breast cancers[J].Oncotarget,2016,7(4):5063-5073.
30 Elsheikh SE,Green AR,Lambros MB,et al.FGFR1 amplification in breast carcinomas:a chromogenic in situ hybridisation analysis[J].Breast Cancer Res,2007,9(2):23.
31 Voutsadakis IA.8p11.23 Amplification in Breast Cancer:Molecular Characteristics,Prognosis and Targeted Therapy[J].J Clin Med,2020,9(10):3079.
32 Bergen ES,Berghoff AS,Steindl A,et al.Androgen receptor is expressed in breast cancer brain metastases[J].Appl Immunohistochem Mol Morphol,2021,29(10):728-733.
33 Wijesinghe HD,Wijesinghe GK,Mansoor Z,et al.Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma[J].BMC women's health,2020,20(1):206.
34 Mooradian AD,Morley JE,Korenman SG.Biological actions of androgens[J].Endocrine reviews,1987,8(1):1-28.
35 Fu WF,Li JJ,Kang SH,et al.The expression,clinicopathologic characteristics,and prognostic value of androgen receptor in breast cancer:a bioinformatics analysis using public databases[J].DNA and cell biology,2020,39(5):864-874.

[1]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[2]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[3]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.
[4]	陈奕心, 孙轶华, 程洋洋, 何凯桐, 郭婷. 术前炎症相关指标与可切除胃癌患者预后的相关性[J]. 实用肿瘤学杂志, 2021, 35(6): 517-522.
[5]	罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.
[6]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[7]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[8]	周天虹, 顾秀瑛, 姚芳, 宋述铭. 乌鲁木齐市2014—2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2021, 35(5): 391-395.
[9]	卢俊蓉, 王惠文, 何东风. SALL4高表达在食管鳞癌临床病理及预后判定中的意义[J]. 实用肿瘤学杂志, 2021, 35(5): 420-425.
[10]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[11]	秦朝, 李江, 郑亚迪, 王飞, 曹巍, 许永杰, 余一雯, 赵亮, 于欣阳, 陈宏达, 任建松, 王勇, 李静, 李霓, 陈万青. 中国城市乳腺癌高危人群筛查依从性及其相关因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 291-296.
[12]	郭兰伟, 张韶凯, 刘曙正, 郑黎阳, 陈琼, 曹小琴, 孙喜斌, 张建功. 河南省城市地区乳腺癌筛查依从性及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 307-313.
[13]	余幼林, 余军林, 胡超华, 沈雄山, 李卫民, 卢婷, 杨峰, 杨青青, 刘程浩. 基于生物信息学方法分析LAYN在甲状腺癌中临床预后价值及对免疫细胞浸润的影响[J]. 实用肿瘤学杂志, 2021, 35(4): 357-364.
[14]	刘文, 乔文波. 程序性死亡蛋白1及其配体在结直肠癌中的临床研究现状[J]. 实用肿瘤学杂志, 2021, 35(4): 370-375.
[15]	董晓平, 张雪, 郭冬利, 贺宇彤. 肺鳞状细胞癌预后相关影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(4): 380-385.